Drug intelligence / Profile preview

midazolam + rocuronium + fentanyl + propofol

Development stage
Unknown
Lead developer
Universidade Estadual Paulista
Modality
Small Molecules
Administration
Intravenous
01

Overview

This refers to a specific drug combination regimen used for the induction and maintenance of general anesthesia in a clinical study conducted by the Universidade Estadual Paulista Júlio de Mesquita Filho (UNESP). The regimen consists of midazolam (a benzodiazepine for sedation), rocuronium (a non-depolarizing neuromuscular blocking agent), fentanyl (an opioid analgesic), and propofol (an intravenous anesthetic). The study specifically investigates the pharmacokinetics and pharmacodynamics of rocuronium within this anesthetic context, particularly focusing on the effects of sepsis, age, and genetic polymorphisms (such as SLCO1A2) on drug metabolism and action. This combination is typically administered intravenously to achieve a state of unconsciousness, analgesia, and muscle relaxation required for surgical procedures.

Other names
general anesthesia-Universidade Estadual Paulista Júlio de Mesquita FilhoGeneral anesthesia (UNESP regimen)
02

Targets

Nicotinic Acetylcholine ReceptorGABRR (GABA-A receptor subunit rho)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on midazolam + rocuronium + fentanyl + propofol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on midazolam + rocuronium + fentanyl + propofol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call